A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations

MeSH terms

• Antineoplastic Agents, Immunological* / adverse effects
• Antineoplastic Agents, Immunological* / therapeutic use
• Antineoplastic Combined Chemotherapy Protocols* / adverse effects
• Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
• Carcinoma, Renal Cell* / drug therapy
• Carcinoma, Renal Cell* / mortality
• Carcinoma, Renal Cell* / pathology
• Clinical Decision-Making*
• Drug Approval*
• Evidence-Based Medicine* / standards
• Humans
• Ipilimumab* / adverse effects
• Ipilimumab* / therapeutic use
• Kidney Neoplasms* / drug therapy
• Kidney Neoplasms* / mortality
• Kidney Neoplasms* / pathology
• Nephrology* / standards
• Nivolumab* / adverse effects
• Nivolumab* / therapeutic use
• Patient Selection
• Treatment Outcome
• Urology* / standards